Zhejiang CONBA PharmaceuticalLtd Past Earnings Performance
Past criteria checks 1/6
Zhejiang CONBA PharmaceuticalLtd has been growing earnings at an average annual rate of 22.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 0.4% per year. Zhejiang CONBA PharmaceuticalLtd's return on equity is 7.7%, and it has net margins of 7.5%.
Key information
22.8%
Earnings growth rate
22.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 0.4% |
| Return on equity | 7.7% |
| Net Margin | 7.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Zhejiang CONBA PharmaceuticalLtd's (SHSE:600572) Problems Go Beyond Weak Profit
Nov 05
It's A Story Of Risk Vs Reward With Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572)
Sep 30Is Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Using Too Much Debt?
Sep 12Is Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHSE:600572) Worth CN¥4.3 Based On Its Intrinsic Value?
Aug 20Here's Why Zhejiang CONBA PharmaceuticalLtd (SHSE:600572) Can Manage Its Debt Responsibly
May 21Revenue & Expenses Breakdown
How Zhejiang CONBA PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 6,462 | 487 | 2,481 | 342 |
| 30 Jun 24 | 6,417 | 458 | 2,511 | 338 |
| 31 Mar 24 | 6,426 | 523 | 2,590 | 314 |
| 31 Dec 23 | 6,733 | 592 | 2,833 | 298 |
| 30 Sep 23 | 6,696 | 752 | 2,869 | 217 |
| 30 Jun 23 | 6,684 | 662 | 2,905 | 194 |
| 31 Mar 23 | 6,430 | 539 | 2,803 | 194 |
| 31 Dec 22 | 6,000 | 358 | 2,582 | 196 |
| 30 Sep 22 | 6,141 | 2,027 | 2,690 | 207 |
| 30 Jun 22 | 6,530 | 1,984 | 2,825 | 214 |
| 31 Mar 22 | 6,678 | 2,073 | 2,945 | 210 |
| 31 Dec 21 | 6,568 | 2,017 | 3,001 | 202 |
| 30 Sep 21 | 6,282 | 129 | 2,974 | 196 |
| 30 Jun 21 | 5,834 | 215 | 2,907 | 190 |
| 31 Mar 21 | 5,821 | 319 | 2,887 | 184 |
| 31 Dec 20 | 5,909 | 453 | 2,979 | 185 |
| 30 Sep 20 | 5,918 | -276 | 3,062 | 182 |
| 30 Jun 20 | 6,313 | -252 | 3,335 | 171 |
| 31 Mar 20 | 6,707 | -342 | 3,753 | 182 |
| 31 Dec 19 | 6,768 | -346 | 3,844 | 183 |
| 30 Sep 19 | 6,855 | 515 | 3,985 | 201 |
| 30 Jun 19 | 6,978 | 652 | 4,025 | 202 |
| 31 Mar 19 | 6,975 | 726 | 3,945 | 191 |
| 31 Dec 18 | 7,018 | 815 | 3,954 | 185 |
| 30 Sep 18 | 7,067 | 879 | 3,896 | 167 |
| 30 Jun 18 | 6,644 | 880 | 3,589 | 225 |
| 31 Mar 18 | 5,979 | 790 | 3,163 | 185 |
| 31 Dec 17 | 5,294 | 711 | 2,655 | 151 |
| 30 Sep 17 | 5,266 | 598 | 2,396 | 96 |
| 30 Jun 17 | 5,311 | 519 | 2,210 | 0 |
| 31 Mar 17 | 5,640 | 477 | 2,112 | 0 |
| 31 Dec 16 | 6,020 | 441 | 2,100 | 0 |
| 30 Sep 16 | 6,092 | 275 | 1,983 | 0 |
| 30 Jun 16 | 6,141 | 308 | 1,952 | 0 |
| 31 Mar 16 | 5,882 | 468 | 1,897 | 0 |
| 31 Dec 15 | 5,302 | 440 | 1,857 | 0 |
| 30 Sep 15 | 4,758 | 770 | 1,899 | 0 |
| 30 Jun 15 | 4,114 | 704 | 1,845 | 0 |
| 31 Mar 15 | 3,746 | 539 | 1,810 | 0 |
| 31 Dec 14 | 3,582 | 552 | 1,760 | 0 |
| 30 Sep 14 | 3,398 | 509 | 1,644 | 0 |
| 30 Jun 14 | 3,212 | 499 | 1,607 | 0 |
| 31 Mar 14 | 2,985 | 451 | 1,537 | 0 |
| 31 Dec 13 | 2,924 | 417 | 1,508 | 0 |
Quality Earnings: 600572 has a large one-off gain of CN¥127.0M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 600572's current net profit margins (7.5%) are lower than last year (11.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600572's earnings have grown significantly by 22.8% per year over the past 5 years.
Accelerating Growth: 600572's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600572 had negative earnings growth (-35.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 600572's Return on Equity (7.7%) is considered low.